DOCSLIB.ORG

ICRS2012 PROGRAMME and ABSTRACTS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ICRS2012 PROGRAMME and ABSTRACTS ND 22 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY KONZERTHAUS FREIBURG FREIBURG IM BREISGAU GERMANY JULY 22 - 27, 2012 ND 22 ANNUAL SYMPOSIUM OF THE INTERNATIONAL CANNABINOID RESEARCH SOCIETY FREIBURG JULY 22 - 27, 2012 PROGRAMME AND ABSTRACTS Symposium Programming by Cortical Systematics LLC Copyright © 2012 International Cannabinoid Research Society Research Triangle Park, NC USA ISBN: 978-0-9658053-5-3 These abstracts may be cited in the scientific literature as follows: Author(s), Abstract Title (2012) 22nd Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page #. Funding for this conference was made possible in part by grant 2R13DA016280 from the National Institute on Drug Abuse. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. ICRS Sponsors Government Sponsors National Institute on Drug Abuse Non-Profit Organization Sponsors Kang Tsou Memorial Fund 2012 Symposium on the Cannabinoids Conference Coordinators Cecilia Hillard, Ph.D. Aron Lichtman, Ph.D. Jason Schechter, Ph.D. Bela Szabo, M.D., Ph.D. Programme Committee Mary Abood, Ph.D. Steve Alexander, Ph.D. Itai Bab, D.M.D. Vincenzo Di Marzo, Ph.D. Javier Fernandez- Ruiz, Ph.D. Matthew Hill, Ph.D. Cecilia Hillard, Ph.D. Allyn Howlett, Ph.D. Aron Lichtman, Ph.D. Mauro Maccarrone, Ph.D. Ken Mackie, M.D. Roger Pertwee, D.Phil, D.Sc. Ruth Ross, Ph.D. Ethan Russo, M.D. Bela Szabo, M.D., Ph.D. Brian Thomas, Ph.D. Jenny Wiley, Ph.D. Student Travel Award Committee Allyn Howlett, Ph.D. Aron Lichtman, Ph.D. Mauro Maccarrone, Ph.D., Chair Ruth Ross, Ph.D. Jenny Wiley, Ph.D. Student Award Committee Chairs Steven Kinsey, Ph.D., Pre- Doc Chair Julián Romero, Ph.D., Post- Doc Chair Mechoulam Award Committee Francis Barth, Ph.D. Vincenzo Di Marzo, Ph.D. Cecilia Hillard, Ph.D. Allyn Howlett, Ph.D. John Huffman, Ph.D., Chair George Kunos, M.D., Ph.D. Gerard Le Fur, Ph.D. Aron Lichtman, Ph.D. Ken Mackie, M.D. Alex Makriyannis, Ph.D. Roger Pertwee, D.Phil, D.Sc. Raj Razdan, Ph.D. Patti Reggio, Ph.D. Murielle Rinaldi- Carmona, Ph.D. 2012 ICRS Board of Directors Executive Director Cecilia Hillard, Ph.D. President Aron Lichtman, Ph.D. President- Elect Jenny Wiley, Ph.D. Past President Mauro Maccarrone, Ph.D. Secretary Steve Alexander, Ph.D. Treasurer Mary Abood, Ph.D. International Secretary Roger Pertwee, D.Phil, D.Sc. Newsletter Editor Brian Thomas, Ph.D. Student Representative Antonio Luchicchi, Ph.D. Managing Director Jason Schechter, Ph.D. Registration: July 22nd, 2012 (16.00 – 19.00) Welcome Reception: 18.30 – 20.00 Day 1 Monday, July 23rd 7.30 Breakfast 8.30 Welcome and Opening Remarks Oral Session 1. Neurodegeneration CHAIRS: ANDREAS ZIMMER AND JAVIER FERNÁNDEZ-RUIZ PAGE # ENDOCANNABINOID HYDROLYSIS Daniel K. Nomura, GENERATES BRAIN PROSTAGLANDINS 8.45 Tarek A. Samad 1 THAT PROMOTE and Benjamin F. Cravatt NEUROINFLAMMATION CANNABINOID LIGANDS DIRECTLY Scott D. Smid MODIFY β-AMYLOID FIBRIL 9.00 2 and Jesper L.V. Mååg FORMATION AND ARE VARIABLY NEUROPROTECTIVE IN VITRO Anne-Caroline Schmöle, Daniele Bano, THE ROLE OF THE 9.15 Pierluigi Nicotera, ENDOCANNABINOID RECEPTOR 3 Andreas Zimmer CB2 IN NEURODEGENERATION and Judith Alferink Ryan Graves, Gareth Pryce, EFFECTS OF GENETIC DELETION AND Michaela Egertová, PHARMACOLOGICAL INHIBITION OF 9.30 Benjamin F. Cravatt, Gavin FATTY ACID AMIDE HYDROLASE IN 4 Giovannoni, Gregory J. EXPERIMENTAL AUTOIMMUNE Michael, Maurice R. Elphick ENCEPHALOMYELITIS and David Baker TARGETING CB1 RECEPTORS 9.45 Nephi Stella AND ABHD6 TO TREAT 5 R6/2 MICE SYMPTOMS Sara Valdeolivas, Onintza Sagredo, Justo PHYTOCANNABINOID-BASED García de Yébenes, Julián 10.00 MEDICINES AS DISEASE-MODIFYING 6 Romero, Roger Pertwee, AGENTS IN HUNTINGTON’S DISEASE Manuel Guzmán and Javier Fernández-Ruiz GENERATION AND Jacqueline L. Blankman, CHARACTERIZATION OF 10.15 Jonathan Z. Long ABHD12–/– MICE, A MODEL OF THE 7 and Benjamin F. Cravatt NEURODEGENERATIVE DISEASE PHARC 10.30 Coffee Break Oral Session 2. Metabolic Regulation / Cardiovascular CHAIRS: GEORGE KUNOS AND MATTHEW HILL George Kunos, Yossi Tam, Resat Cinar, PERIPHERAL CB1R INVERSE AGONISM Jeih-San Liow, 11.00 REDUCES DIET-INDUCED OBESITY BY 8 Robert Innis, REVERSING LEPTIN RESISTANCE Robert Chorvat and John F. McElroy ACTIVATION OF HYPOTHALAMIC Matthew N. Hill, Nicole FATTY ACID AMIDE HYDROLASE BY P. Bowles, Tiffany T. Lee 11.15 LEPTIN: REGULATION OF FOOD 9 Cecilia J. Hillard INTAKE AND EFFECTS OF and Bruce S. McEwen DIET-INDUCED OBESITY Susan Krzysik-Walker, THE CANNABINOID RECEPTOR Isabel Gonzalez- INVERSE AGONIST AM251 Mariscal, Morten 11.30 ALTERS MITOCHONDRIAL 10 Scheibye-Knudsen, PHYSIOLOGY VIA PROTEOLYTIC Fred Indig DEGRADATON OF ERRα and Michel Bernier CANNABIDIOL IMPROVES IMPAIRED A J Wheal, M D Randall ENDOTHELIAL FUNCTION IN 11.45 11 and S E O’Sullivan FEMORAL ARTERIES FROM ZUCKER DIABETIC RATS THE EFFECTS OF ANANDAMIDE William H Hind ON PERMEABILITY IN 12.00 12 and Saoirse E O’Sullivan A CELL CULTURE MODEL OF THE BLOOD-BRAIN BARRIER Sabina Adhikary, MODULATION OF INFLAMMATORY Hongbo Li, Mario CELL INVASION OF THE CNS 12.15 Skarica, Weimin Kong, 13 BY A CANNABINOID-2 SELECTIVE Anu Mahadevan, Doina AGONIST AFTER INJURY Ganea and Ronald Tuma 12.30-14.00 Lunch Oral Session 3. Psychiatric Diseases / Learning & Memory CHAIRS: BEAT LUTZ AND SARA JANE WARD CANNABINOIDS PREVENT THE Eti Ganon-Elazar 14.00 DEVELOPMENT OF POST-TRAUMA 14 and Irit Akirav SYMPTOMS IN A RAT MODEL OF PTSD Ozge Gunduz-Cinar, Caitlin M Schaapveld, Kathryn P. MacPherson, Resat Cinar, Joyonna Gamble- George, Karen Sugden, Benjamin Williams, Grzegorz Godlewski, Teniel ANANDAMIDE IN AMYGDALA- S Ramikie, Adam X. Gorka, MEDIATED FEAR EXTINCTION, THREAT 14.15 15 Shakiru O. Alapafuja, PROCESSING AND STRESS-REACTIVITY: Spyros P. Nikas, A TRANSLATIONAL STUDY Alexandros Makriyannis, Richie Poulton, Sachin Patel, Ahmad R. Hariri, Avshalom Caspi, Terrie E. Moffitt, George Kunos and Andrew Holmes MEDICAL CANNABIS/MARIJUANA USE IN POST-TRAUMATIC STRESS 14.30 Ilya Reznik 16 DISORDER: A LONGITUDINAL FOLLOW-UP STUDY ANXIOGENIC-LIKE EFFECT OF Moriah Iverson THC IS LOST IN MICE LACKING 14.45 17 and Cecilia J. Hillard BETA-ARRESTIN-2: EVIDENCE FOR SEX-DEPENDENT EFFECTS Daniela Hauer, Piray ENDOCANNABINOID- Atsak, Raquel V. Fornari, GLUCOCORTICOID INTERACTION IN 15.00 Patrizia Campolongo, 18 THE BASOLATERAL AMYGDALA Gustav Schelling DURING MEMORY CONSOLIDATION and Benno Roozendaal Maria Morena, Viviana Trezza, Sergio Scaccianoce, CANNABINOIDS MODULATION OF Alessandro Pasquale, OBJECT RECOGNITION MEMORY IN 15.15 Vincenzo Cuomo, 19 RATS: INVOLVEMENT OF THE Gustav Schelling, GLUCOCORTICOID SYSTEM Benno Roozendaal and Patrizia Campolongo Xiang-Qun Xie, Rentian Feng, Peng Yang, Junpei Teramachi, Qin Tong, CANNABINOID RECEPTOR CB2. 15.30 Lirong Wang, Zhaojun A NEW DRUG TARGET FOR 20 Xie, Kyaw Myint, MULTIPLE MYELOMA INTERVENTION Noriyoshi Kurihara and David G. Roodman Poster Session 1 15.45-17.45 P1 Coffee Presidential Plenary Speaker “PLANNING RESEARCH FOR THE NEXT HALF A CENTURY” 18.00 Raphael Mechoulam, Ph.D. Institute for Drug Research Hebrew University of Jerusalem Day 2 Tuesday, July 24th 7.30 Breakfast Oral Session 4. Receptor Signaling CHAIRS: HEATHER BRADSHAW AND MARY ABOOD Mark Bauer, Andrea Chicca, Stefanie IDENTIFICATION OF A FAMILY OF Hofer-Reyes, Marco PEPTIDE ENDOCANNABINOIDS 8.30 Tamborrini, David Eisen, (PEPCANS): EVIDENCE FOR 21 Oliver Poetz, ALLOSTERIC MODULATION Gerd Pluschke OF CB1 RECEPTORS and Jürg Gertsch THE CB1 RECEPTOR ALLOSTERIC MODULATOR, ORG 27569, Maria Grazia Cascio, HAS DIFFERENT EFFECTS ON THE 8.45 Daniele Bolognini POTENCIES WITH WHICH CP55940, 22 and Roger G. Pertwee O-2050 AND SR141716A DISPLACE [3H]CP55940 OR [3H]SR141716A FROM MOUSE BRAIN CB1 RECEPTORS Derek M. Shore, Dow P. IDENTIFICATION OF THE ORG27569 Hurst, Herb Seltzman, BINDING SITE AT THE CB1 RECEPTOR: Gemma Baillie, 9.00 IMPORTANCE OF K3.28 INTERACTION 23 Ruth Ross, Jahan P. TO THE ORG27569 EFFECT ON BASAL Marcu, Mary Abood SIGNALING and Patricia H. Reggio Michelle Glass, Erin Cawston, Courtney ALLOSTERIC MODULATION OF 9.15 24 Breen, William Redmond HUMAN CB1 RECEPTORS and Mark Connor Eugen Brailoiu, G. Cristina Brailiou, Elena Deliu, FUNCTIONAL INTRACELLULAR 9.30 25 Haleli Sharir, CANNABINOID RECEPTORS Pingwei Zhao and Mary E. Abood Lawrence C. Blume, CANNABINOID RECEPTOR Caroline E. Bass, INTERACTING PROTEIN (CRIP1A) 9.45 George D. Dalton, MODULATES CB1 RECEPTOR 26 Dana E. Selley TRAFFICKING, ACTIVITY and Allyn C. Howlett AND SIGNALING Natasha L Grimsey, UNUSUAL TRAFFICKING OF Duneeshya Gunasekara, CANNABINOID RECEPTOR 2: 10.00 Erin Cawston, 27 AGONIST-INDUCED UPREGULATION Catherine E Goodfellow OF SURFACE RECEPTORS and Michelle Glass 21 NOVEL N-ACYL AMIDES, Heather B. Bradshaw, INCLUDING N-DOCOSAHEXEANOYL 10.15 Siham Raboune ETHANOLAMINE, HAVE ACTIVITY AT 28 and Jordyn M. Stuart TRPV1-4 THE PUTATIVE IONOTROPIC CANNABINOID RECEPTORS Christopher J. Fowler, ASSOCIATION BETWEEN TUMOUR 10.30 Peter Hammarsten and PAKT AND CB1 RECEPTOR EXPRESSION 29 Mariateresa Cipriano IN PROSTATE CANCER 10.45 Coffee Break Oral Session 5. Gastrointestinal regulation CHAIRS: STEVEN KINSEY AND MARIO VAN DER STELT REMARKABLE POTENCY OF ∆9-THC IN Steven G. Kinsey, BLOCKING GASTRIC HEMORRHAGES 11.00 Erica C. Cole 30 CAUSED BY CYCLOOXYGENASE and Aron H. Lichtman
Load more

Recommended publications
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Marijuana: Drug of Abuse Or Therapeutic Option? Learning Objectives
    Handout for the Neuroscience Education Institute (NEI) online activity: Marijuana: Drug of Abuse or Therapeutic Option? Learning Objectives • Explain how cannabinoids affect the body and the brain • Educate patients about: – Evidence of efficacy for mental health and other conditions – Potential risks of cannabis use Timeline 1989? 90?: Discovery of ~2000 BC: binding site 2015: Elimination of Chinese 1943: Marijuana for THC— 1992: US Public Health emperors removed from CB1 Endogenous Service oversight cannabinoid recommend listing as a 1963: 1964: THC receptor for obtaining anandamide marijuana as medication in US Cannabidiol isolated marijuana for discovered medicine Pharmacopeia isolated research purposes 1995: 1851: Marijuana 1961: United 1970: Marijuana is Endogenous Aug 11 2016: listed as a Nations Single labeled Schedule I cannabinoid 2-AG DEA declines to medication in US Convention on by the US discovered reschedule Pharmacopeia Narcotic Drugs: Substance Abuse marijuana marijuana said to Act; this restricts be dangerous with both personal use no medical value and access for research purposes THE INTERSECTION OF THE HEALTHCARE AND CANNABIS INDUSTRIES What is Cannabis? 500 chemicals 100 cannabinoids Best understood: THC and CBD Scheduling of Controlled Substances No medicinal value, high Moderate to Lower High potential Low potential potential for low potential potential for for abuse for abuse abuse for abuse abuse Schedule I Schedule II Schedule III Schedule IV Schedule V Marijuana Cocaine Tylenol w/ Tramadol Robitussin AC Heroin
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Cannabinoid Receptor and Inflammation
    Cannabinoid Receptor and Inflammation Newman Osafo1, Oduro Yeboah1, Aaron Antwi1, and George Ainooson1 1Kwame Nkrumah University of Science and Technology September 11, 2020 Abstract The eventual discovery of endogenous cannabinoid receptors CB1 and CB2 and their endogenous ligands has generated interest with regards to finally understanding the endocannabinoid system. Its role in the normal physiology of the body and its implication in pathological states such as cardiovascular diseases, neoplasm, depression and pain have been subjects of scientific interest. In this review the authors focus on the endogenous cannabinoid pathway, the critical role of cannabinoid receptors in signaling and mediation of neurodegeneration and other inflammatory responses as well as its potential as a drug target in the amelioration of some inflammatory conditions. Though the exact role of the endocannabinoid system is not fully understood, the evidence found leans heavily towards a great potential in exploiting both its central and peripheral pathways in disease management. Cannabinoid therapy has already shown great promise in several preclinical and clinical trials. 1.0 Introduction Ethnopharmacological studies have shown the use of Cannabis sativa in traditional medicine for over a thousand years, with its widespread use promoted by its psychotropic effects (McCoy, 2016; Turcotte et al., 2016). The discovery of a receptor within human body, that is selectively activated by cannabinoids suggested the presence of at least one endogenous ligand for this receptor. This is confirmed by the discovery of two endogenously synthesized lipid mediators, 2-arachidonoyl-glycerol and arachidonoylethanolamide, which function as high-affinity ligands for a subfamily of cannabinoid receptors ubiquitously distributed in the central nervous system, known as the CB1 receptors (Turcotte et al., 2016).
    [Show full text]
  • Concert/Ceilidh
    FAMILY RESTAURANT WATERSIDE RESTAURANT Come Treat Yourself and Your Family to an evening of Dining Out - Great Meals and Desserts - Children’s Menu Available 293 Commercial Street - Overlooking The Harbour in Downtown North Sydney On Archibald’s Wharf Open Daily from 11 AM - PHONE 794-1700 NORTHSIDE FREE FREE Take Copy One THIS WEEK Online VOLUME 2 - #34 - Aug. 23 - Aug. 30 - Florence - Bras d’Or - Pt. Aconi - Sydney Mines - North Sydney Games, Entertainment And Grand Openings NEW BUSINESS OPENED - SPORTSWEAR & GEAR For those of you who are not in this edition to see the live There’s a new business opened in the Old Library Building sure “where the action is”, then entertainment they are provid- this week’s edition will be a big ing each weekend. on Commercial Street in North Sydney and it is designed to help to you. Read about the two Grand help you with your selection of activity and casual apparel. You may be wondering what Openings (Page 7) for Nora’s See the story on page 2 for complete details of the store, the to do with this wonderful New To You and the Emera hours of operation and how to contact them. weather we’ve been blessed Centre with its list of great with the last few weeks. sport and music events It’s called Escape Outdoors and you no longer have to travel There’s no better time to take scheduled for September. outside Cape Breton to get this line of outdoor sportswear. in some events such as the There’s lots to see and do! Canada 55+ Games which get underway in various Cape Breton communities and ven- City Nails ues starting August 29th.
    [Show full text]
  • Identification of Biomarkers for Sarcoidosis and Tuberculosis of The
    DATABASE ANALYSIS e-ISSN 1643-3750 © Med Sci Monit, 2020; 26: e925438 DOI: 10.12659/MSM.925438 Received: 2020.04.26 Accepted: 2020.05.11 Identification of Biomarkers for Sarcoidosis and Available online: 2020.05.28 Published: 2020.07.23 Tuberculosis of the Lung Using Systematic and Integrated Analysis Authors’ Contribution: ABCEF 1 Min Zhao 1 Department of Respiratory and Critical Care Medicine, The Second Hospital of Study Design A BCE 1 Xin Di Jilin University, Changchun, Jilin, P.R. China Data Collection B 2 Department of Oncology and Hematology, The Second Hospital of Jilin University, Statistical Analysis C CDE 2 Xin Jin Changchun, Jilin, P.R. China Data Interpretation D BF 1 Chang Tian Manuscript Preparation E CF 1 Shan Cong Literature Search F Funds Collection G BF 1 Jiangyin Liu ABDEG 1 Ke Wang Corresponding Author: Ke Wang, e-mail: [email protected] Source of support: This study was supported by the Technology Research Funds of Jilin Province (20190303162SF), the Natural Science Foundation of Jilin Province (20180101103JC), and the Medical and Health Project Funds of Jilin Province (20191102012YY) Background: Sarcoidosis (SARC) is a multisystem inflammatory disease of unknown etiology and pulmonary tuberculosis (PTB) is caused by Mycobacterium tuberculosis. Both of these diseases affect lungs and lymph nodes and share similar clinical manifestations. However, the underlying mechanisms for the similarities and differences in ge- netic characteristics of SARC and PTB remain unclear. Material/Methods: Three datasets (GSE16538, GSE20050, and GSE19314) were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in SARC and PTB were identified using GEO2R online analyz- er and Venn diagram software.
    [Show full text]
  • Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and Other Transcription Factors
    CARBOXYLESTERASES: PHARMACOLOGICAL INHIBITION REGULATED EXPRESSION AND TRANSCRIPTIONAL INVOLVEMENT OF NUCLEAR RECEPTORS AND OTHER TRANSCRIPTION FACTORS Yuanjun Shen1, Zhanquan Shi2 and Bingfang Yan2,3 Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 USA. Address Correspondence to: Dr. Bingfang Yan Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 Phone: (513) 558-6297 Fax: (513) 558-3233 E-mail: [email protected] Running Title: Regulated expression and inhibited activity of carboxylesterases FOOTNOTES 1 Current address: Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh Department of Medicine, Pittsburgh, PA 15261, USA. 2 Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA 3 To whom correspondence should be addressed. 4 This work was supported by National Institutes of Health Grants R01GM61988 and R01EB018748. 5 Abbreviation used: CAR, Constitutive androstane receptor; CES1, carboxylesterase-1; DEC1, Differentiated embryo chondrocyte-1; 5-FU: Fluorouracil; GR, Glucocorticoid receptor; IL-6, Interlekin- 6; LPS, Lipopolysaccharides; Nrf2, Nuclear factor (erythroid-derived 2)-like 2; p53, Tumor protein p53; PXR, Pregnane X receptor Carboxylesterases (CESs, E.C.3.1.1.1) constitute a large class of enzymes that determine the therapeutic efficacy and toxicity of ester/amide drugs. Without exceptions, all mammalian species studied express multiple forms of carboxylesterases. Two human carboxylesterases, CES1 and CES2, are major contributors to hydrolytic biotransformation. Recent studies have identified therapeutic agents that potently inhibit carboxylesterases-based catalysis. Some of them are reversible whereas others irreversible. The adrenergic antagonist carvedilol, for example, reversibly inhibits CES2 but this carboxylesterase is irreversibly inhibited by orlistat, a popular anti-obesity medicine.
    [Show full text]
  • NIH Public Access Author Manuscript Drug Alcohol Depend
    NIH Public Access Author Manuscript Drug Alcohol Depend. Author manuscript; available in PMC 2015 October 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Drug Alcohol Depend. 2014 October 1; 143: 251–256. doi:10.1016/j.drugalcdep.2014.08.004. Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine- seeking behavior in rats* Li Jinga,b, Yanyan Qiua, Yanan Zhangc, and Jun-Xu Lia aDepartment of Pharmacology and Toxicology, University at Buffalo, Buffalo, New York, USA bDepartment of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China cResearch Triangle Institute, Research Triangle Park, North Carolina, USA Abstract Background—Cannabinoid CB1 receptors play an essential role in drug addiction. Given the side effect profiles of orthosteric CB1 antagonism, new strategies have been attempted to modulate this target, such as CB1 receptor allosteric modulation. However, the effect of CB1 allosteric modulation in drug addiction is unknown. The present study examined the effects of the CB1 receptor allosteric modulator ORG27569 on the reinstatement of cocaine- and methamphetamine- seeking behavior in rats. Methods—Rats were trained to self-administer 0.75 mg/kg cocaine or 0.05 mg/kg methamphetamine in 2-hr daily sessions for 14 days which was followed by 7 days of extinction sessions in which rats responded on the levers with no programmed consequences. On reinstatement test sessions, rats were administered ORG27569 (1.0, 3.2, 5.6 mg/kg, i.p.) or SR141716A (3.2 mg/kg, i.p.) 10 min prior to re-exposure to cocaine- or methamphetamine-paired cues or a priming injection of cocaine (10 mg/kg, i.p.) or methamphetamine (1 mg/kg, i.p.).
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
    cancers Review Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives 1, 1, 1 2 1 Laurence Pellerin y, Lorry Carrié y , Carine Dufau , Laurence Nieto , Bruno Ségui , 1,3 1, , 1, , Thierry Levade , Joëlle Riond * z and Nathalie Andrieu-Abadie * z 1 Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III Paul-Sabatier, Inserm 1037, 2 avenue Hubert Curien, tgrCS 53717, 31037 Toulouse CEDEX 1, France; [email protected] (L.P.); [email protected] (L.C.); [email protected] (C.D.); [email protected] (B.S.); [email protected] (T.L.) 2 Institut de Pharmacologie et de Biologie Structurale, CNRS, Université Toulouse III Paul-Sabatier, UMR 5089, 205 Route de Narbonne, 31400 Toulouse, France; [email protected] 3 Laboratoire de Biochimie Métabolique, CHU Toulouse, 31059 Toulouse, France * Correspondence: [email protected] (J.R.); [email protected] (N.A.-A.); Tel.: +33-582-7416-20 (J.R.) These authors contributed equally to this work. y These authors jointly supervised this work. z Received: 15 September 2020; Accepted: 23 October 2020; Published: 27 October 2020 Simple Summary: Melanoma is a devastating skin cancer characterized by an impressive metabolic plasticity. Melanoma cells are able to adapt to the tumor microenvironment by using a variety of fuels that contribute to tumor growth and progression. In this review, the authors summarize the contribution of the lipid metabolic network in melanoma plasticity and aggressiveness, with a particular attention to specific lipid classes such as glycerophospholipids, sphingolipids, sterols and eicosanoids.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink Et Al
    US 20120022039A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink et al. (43) Pub. Date: Jan. 26, 2012 (54) NOVEL SUBSTITUTED INDANES, METHOD Publication Classification FOR THE PRODUCTION THEREOF, AND USE (51) Int. Cl. THEREOF AS DRUGS A 6LX 3L/397 (2006.01) C07D 207/06 (2006.01) C07D 2L/22 (2006.01) C07D 22.3/04 (2006.01) (75) Inventors: Lothar Schwink, Frankfurt am C07D 22L/22 (2006.01) Main (DE); Siegfried Stengelin, C07C 235/54 (2006.01) Frankfurt am Main (DE); Matthias C07D 307/14 (2006.01) Gossel, Frankfurt am Main (DE); A63L/35 (2006.01) Klaus Wirth, Frankfurt am Main A6II 3/40 (2006.01) (DE) A6II 3/445 (2006.01) A6II 3/55 (2006.01) A63L/439 (2006.01) A6II 3/66 (2006.01) (73) Assignee: SANOFI, Paris (FR) A6II 3/34 (2006.01) A6IP3/10 (2006.01) A6IP3/04 (2006.01) A6IP3/06 (2006.01) (21) Appl. No.: 13/201410 A6IPL/I6 (2006.01) A6IP3/00 (2006.01) C07D 309/04 (2006.01) (52) U.S. Cl. .................... 514/210.01; 549/426: 548/578; (22) PCT Filed: Feb. 12, 2010 546/205; 540/484; 546/112:564/176; 549/494; 514/459:514/408: 514/319; 514/212.01; 514/299; 514/622:514/471 (86). PCT No.: PCT/EP2010/051796 (57) ABSTRACT The invention relates to substituted indanes and derivatives S371 (c)(1), thereof, to physiologically acceptable salts and physiologi (2), (4) Date: Oct. 4, 2011 cally functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according (30) Foreign Application Priority Data to the invention or derivative thereof, and to the use of the Substituted indanes according to the invention and to deriva Feb.
    [Show full text]